The Utility of Tumour Markers in Assessing the Response to Chemotherapy in Advanced Bladder Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2000 Jun 23

PMID 10864203

Citations 7

Authors

A M Cook

R A Huddart

G Jay

A Norman

D P Dearnaley

A Horwich

Affiliations

Soon will be listed here.

Abstract

In patients with advanced bladder cancer receiving chemotherapy, early assessment of response can avoid unnecessary toxicity. The aim of this study was to assess the role of tumour markers in monitoring response. Serum levels of one or more of markers beta human chorionic gonadotrophin (betahCG), carcinoembryomic antigen (CEA), CA125 and CA19.9 were measured in 74 patients with advanced bladder cancer receiving chemotherapy from 1992 to 1997. Forty-three of 74 (58%) of patients had at least one raised marker (1.5 times upper limit of normal range). This was more common in patients with extra-pelvic disease than in those with disease confined to the pelvis (P = 0.002). Thirty-eight of 78 (49%) assessable patients had a radiological response. Neither clinical response (P = 0.81) nor survival (P = 0.16) differed between marker-negative and marker-positive patients. Clinical response was strongly related to marker response in the 35 comparable patients (P = 0.0001). No patient had a clinical response without response of at least one marker. Ninety per cent of patients who achieved a marker response had done so by 8 weeks. Monitoring of tumour markers in patients with advanced bladder cancer can help predict the response to chemotherapy.

Citing Articles

Serum Tumor Markers for Muscle-Invasive Bladder Cancer in Clinical Practice: A Narrative Review.

Doshi C, Zahir M, Dadabhoy A, Escobar D, Xia L, Daneshmand S Cancers (Basel). 2025; 17(5).

PMID: 40075577 PMC: 11898461. DOI: 10.3390/cancers17050728.

Aberrant trophoblastic differentiation in human cancer: An emerging novel therapeutic target (Review).

Chang C, Chen Y, Wang Y, Chen H, Hsu C, Lin K Oncol Rep. 2024; 51(3).

PMID: 38240107 PMC: 10823338. DOI: 10.3892/or.2024.8701.

CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis.

Lin H, Hu R, Chen H, Lin C, Lee C, Chou C Cancers (Basel). 2023; 15(3).

PMID: 36765770 PMC: 9913454. DOI: 10.3390/cancers15030813.

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

Choueiri T, Jacobus S, Bellmunt J, Qu A, Appleman L, Tretter C J Clin Oncol. 2014; 32(18):1889-94.

PMID: 24821883 PMC: 7057274. DOI: 10.1200/JCO.2013.52.4785.

Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract.

Douglas J, Sharp A, Chau C, Head J, Drake T, Wheater M Br J Cancer. 2014; 110(7):1759-66.

PMID: 24556622 PMC: 3974095. DOI: 10.1038/bjc.2014.89.

References

Williams G, Colbeck R, Crawford S . Treatment of bladder carcinoma using a germ cell chemotherapy protocol. Br J Urol. 1990; 65(5):473-7. DOI: 10.1111/j.1464-410x.1990.tb14789.x. View

Logothetis C, Dexeus F, Finn L, Sella A, Amato R, Ayala A . A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990; 8(6):1050-5. DOI: 10.1200/JCO.1990.8.6.1050. View

McLoughlin J, Pepera T, Bridger J, Williams G . Serum and urinary levels of beta human chorionic gonadotrophin in patients with transitional cell carcinoma. Br J Cancer. 1991; 63(5):822-4. PMC: 1972392. DOI: 10.1038/bjc.1991.182. View

Loehrer Sr P, Einhorn L, Elson P, Crawford E, Kuebler P, Tannock I . A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10(7):1066-73. DOI: 10.1200/JCO.1992.10.7.1066. View

Marcillac I, Troalen F, Bidart J, Ghillani P, Ribrag V, Escudier B . Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res. 1992; 52(14):3901-7. View

Schmidt A, Bub P, Ruther U, Eisenberger F . Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy. Eur Urol. 1992; 21 Suppl 1:10-2. DOI: 10.1159/000474879. View

Marcillac I, Cottu P, Theodore C, Terrier-Lacombe M, Bellet D, Droz J . Free hCG-beta subunit as tumour marker in urothelial cancer. Lancet. 1993; 341(8856):1354-5. DOI: 10.1016/0140-6736(93)90872-e. View

Moutzouris G, Yannopoulos D, Barbatis C, Zaharof A, Theodorou C . Is beta-human chorionic gonadotrophin production by transitional cell carcinoma of the bladder a marker of aggressive disease and resistance to radiotherapy?. Br J Urol. 1993; 72(6):907-9. DOI: 10.1111/j.1464-410x.1993.tb16294.x. View

Pectasides D, Bafaloucos D, Antoniou F, Gogou L, Economides N, Varthalitis J . TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol. 1996; 19(3):271-7. DOI: 10.1097/00000421-199606000-00013. View

10.

Iles R, Persad R, Trivedi M, Sharma K, Dickinson A, Smith P . Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol. 1996; 77(1):61-9. DOI: 10.1046/j.1464-410x.1996.82910.x. View

11.

Fossa S, Sternberg C, Scher H, Theodore C, Mead B, Dearnaley D . Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer. 1996; 74(10):1655-9. PMC: 2074866. DOI: 10.1038/bjc.1996.605. View

12.

Toubert M, Hennequin C, Housset M . Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study. J Clin Oncol. 1997; 15(12):3446-50. DOI: 10.1200/JCO.1997.15.12.3446. View

13.

Dexeus F, Logothetis C, Hossan E, SAMUELS M . Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. J Urol. 1986; 136(2):403-7. DOI: 10.1016/s0022-5347(17)44882-8. View

14.

Wurzel R, Yamase H, Nieh P . Ectopic production of human chorionic gonadotropin by poorly differentiated transitional cell tumors of the urinary tract. J Urol. 1987; 137(3):502-4. DOI: 10.1016/s0022-5347(17)44088-2. View

15.

Abel P, CORNELL C, Buamah P, Williams G . Assessment of serum CA 19.9 as a tumour marker in patients with carcinoma of the bladder and prostate. Br J Urol. 1987; 59(5):427-9. DOI: 10.1111/j.1464-410x.1987.tb04840.x. View

16.

Sternberg C, Yagoda A, Scher H, Watson R, Herr H, Morse M . M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988; 139(3):461-9. DOI: 10.1016/s0022-5347(17)42494-3. View

17.

Iles R, Jenkins B, Oliver R, Blandy J, Chard T . Beta human chorionic gonadotrophin in serum and urine. A marker for metastatic urothelial cancer. Br J Urol. 1989; 64(3):241-4. DOI: 10.1111/j.1464-410x.1989.tb06006.x. View

18.

Guarnaccia S, Pais V, Grous J, Spirito N . Adenocarcinoma of the urachus associated with elevated levels of CA 125. J Urol. 1991; 145(1):140-1. DOI: 10.1016/s0022-5347(17)38271-x. View